| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Patrick Weydt, Soyon Hong, Anke Witting, Thomas Möller, Nephi Stella, Michel Klio. Cannabinol delays symptom onset in SOD1 (G93A) transgenic mice without affecting survival. Amyotrophic lateral sclerosis and other motor neuron disorders : official publication of the World Federation of Neurology, Research Group on Motor Neuron Diseases. vol 6. issue 3. 2006-01-04. PMID:16183560. |
however, delta(9)-tetrahydrocannabinol (delta(9)-thc), the predominant cannabinoid in marijuana, induces mind-altering effects and is partially addictive, compromising its clinical usefulness. |
2006-01-04 |
2023-08-12 |
mouse |
| Mahmoud A Elsohly, Desmond Slad. Chemical constituents of marijuana: the complex mixture of natural cannabinoids. Life sciences. vol 78. issue 5. 2005-12-22. PMID:16199061. |
chemical constituents of marijuana: the complex mixture of natural cannabinoids. |
2005-12-22 |
2023-08-12 |
human |
| Ganesh A Thakur, Richard I Duclos, Alexandros Makriyanni. Natural cannabinoids: templates for drug discovery. Life sciences. vol 78. issue 5. 2005-12-22. PMID:16242157. |
recent studies have elucidated the biosynthetic pathway of cannabinoids and have highlighted the preference for a c-3 n-pentyl side chain in the most prominently represented cannabinoids from cannabis sativa and their medicinally important decarboxylation products. |
2005-12-22 |
2023-08-12 |
Not clear |
| Ganesh A Thakur, Richard I Duclos, Alexandros Makriyanni. Natural cannabinoids: templates for drug discovery. Life sciences. vol 78. issue 5. 2005-12-22. PMID:16242157. |
structure-activity relationship (sar) studies performed on delta(9)-tetrahydrocannabinol (delta(9)-thc), the key psychoactive ingredient of cannabis, and its synthetic analogues have identified the c-3 side chain as the key pharmacophore for ligand affinity and selectivity for the known cannabinoid receptors and for pharmacological potency. |
2005-12-22 |
2023-08-12 |
Not clear |
| Maciej Kochanowski, Maria Kał. Tetrahydrocannabinols in clinical and forensic toxicology. Przeglad lekarski. vol 62. issue 6. 2005-12-21. PMID:16225128. |
cannabinoids are the natural constituents of marihuana (cannabis). |
2005-12-21 |
2023-08-12 |
human |
| Rebecka Coles, Thomas T Clements, Gordon J Nelson, Gwendolyn A McMillin, Francis M Urr. Simultaneous analysis of the Delta9-THC metabolites 11-nor-9-carboxy-Delta9-THC and 11-hydroxy-Delta9-THC in meconium by GC-MS. Journal of analytical toxicology. vol 29. issue 6. 2005-12-09. PMID:16168173. |
the analysis of 246 cannabinoid screen positive specimens illustrated the importance of including the 11-hydroxy-thc in a meconium marijuana confirmation: 16 specimens confirmed positive for 11-hydroxy-thc only, resulting in a 6.5% increase in the positivity rate compared to 9-carboxy-thc alone. |
2005-12-09 |
2023-08-12 |
Not clear |
| Mario van der Stelt, Vincenzo Di Marz. Cannabinoid receptors and their role in neuroprotection. Neuromolecular medicine. vol 7. issue 1-2. 2005-12-08. PMID:16052037. |
two g protein-coupled receptors for marijuana's psychoactive component, delta9-tetrahydrocannabinol, have been cloned to date, the cannabinoid cb1 and cb2 receptors. |
2005-12-08 |
2023-08-12 |
Not clear |
| Natalia Battista, Filomena Fezza, Mauro Maccarron. Endocannabinoids and their involvement in the neurovascular system. Current neurovascular research. vol 1. issue 2. 2005-12-05. PMID:16185189. |
anandamide (n-arachidonoylethanolamine; aea) and 2-arachidonoylglycerol are the main endogenous agonists of cannabinoid receptors, able to mimic several pharmacological effects of delta(9)-tetrahydrocannabinol, the active principle of cannabis sativa preparations like hashish and marijuana. |
2005-12-05 |
2023-08-12 |
Not clear |
| J Ludovic Croxford, Kegiang Wang, Stephen D Miller, David M Engman, Kevin M Tyle. Effects of cannabinoid treatment on Chagas disease pathogenesis: balancing inhibition of parasite invasion and immunosuppression. Cellular microbiology. vol 7. issue 11. 2005-11-29. PMID:16207246. |
refined use of cannabinoids may prove therapeutic in the future, but our results raise concern about the effect of cannabis use on those chronically infected by t. cruzi and on heart cell homeostasis generally. |
2005-11-29 |
2023-08-12 |
mouse |
| Robert Melamed. Cannabis and tobacco smoke are not equally carcinogenic. Harm reduction journal. vol 2. 2005-11-08. PMID:16232311. |
cannabis smoke contains cannabinoids whereas tobacco smoke contains nicotine. |
2005-11-08 |
2023-08-12 |
Not clear |
| L R Gowing, R L Ali, P Christie, J M Whit. Therapeutic use of cannabis: clarifying the debate. Drug and alcohol review. vol 17. issue 4. 2005-10-31. PMID:16203511. |
at present the evidence is limited, it mostly relates to the use of synthetic cannabinoids, and much of it fails to compare cannabis with the best therapies available for the conditions of interest. |
2005-10-31 |
2023-08-12 |
Not clear |
| L R Gowing, R L Ali, P Christie, J M Whit. Therapeutic use of cannabis: clarifying the debate. Drug and alcohol review. vol 17. issue 4. 2005-10-31. PMID:16203511. |
further research is required to clarify the efficacy of pure, synthetic cannabinoids compared to cannabis, the most effective route of administration, and the importance of delivering a known dose. |
2005-10-31 |
2023-08-12 |
Not clear |
| Sonja Ständer, Martin Schmelz, Dieter Metze, Thomas Luger, Roman Rukwie. Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. Journal of dermatological science. vol 38. issue 3. 2005-10-27. PMID:15927811. |
cannabinoid receptors mediate the psychopharmacological action of marijuana and have been localized in the central and peripheral nervous system as well as on cells of the immune system. |
2005-10-27 |
2023-08-12 |
human |
| Andrea L Small-Howard, Lori M N Shimoda, Chaker N Adra, Helen Turne. Anti-inflammatory potential of CB1-mediated cAMP elevation in mast cells. The Biochemical journal. vol 388. issue Pt 2. 2005-10-24. PMID:15669919. |
cannabinoids are broadly immunosuppressive, and anti-inflammatory properties have been reported for certain marijuana constituents and endogenously produced cannabinoids. |
2005-10-24 |
2023-08-12 |
Not clear |
| Zizhong Li, Andrew Gifford, Qian Liu, Rajesh Thotapally, Yu-Shin Ding, Alexandros Makriyannis, S John Gatle. Candidate PET radioligands for cannabinoid CB1 receptors: [18F]AM5144 and related pyrazole compounds. Nuclear medicine and biology. vol 32. issue 4. 2005-10-18. PMID:15878505. |
the mammalian brain contains abundant g protein-coupled cannabinoid cb(1) receptors that respond to delta(9)-tetrahydrocannabinol, the active ingredient of cannabis. |
2005-10-18 |
2023-08-12 |
Not clear |
| Kazuhisa Matsuda, Yukio Mikami, Kazunori Takeda, Shoji Fukuyama, Shinichi Egawa, Makoto Sunamura, Ikurou Maruyama, Seiki Matsun. The cannabinoid 1 receptor antagonist, AM251, prolongs the survival of rats with severe acute pancreatitis. The Tohoku journal of experimental medicine. vol 207. issue 2. 2005-10-14. PMID:16141678. |
cannabinoid means a mind-active material in cannabis (marijuana). |
2005-10-14 |
2023-08-12 |
rat |
| Carol Hamelink, Aidan Hampson, David A Wink, Lee E Eiden, Robert L Eska. Comparison of cannabidiol, antioxidants, and diuretics in reversing binge ethanol-induced neurotoxicity. The Journal of pharmacology and experimental therapeutics. vol 314. issue 2. 2005-09-30. PMID:15878999. |
because the nonpsychoactive cannabinoid cannabidiol (cbd) was previously shown in vitro to prevent glutamate toxicity through its ability to reduce oxidative stress, we evaluated cbd as a neuroprotectant in a rat binge ethanol model. |
2005-09-30 |
2023-08-12 |
rat |
| Jonathan F Fay, Thomas D Dunham, David L Farren. Cysteine residues in the human cannabinoid receptor: only C257 and C264 are required for a functional receptor, and steric bulk at C386 impairs antagonist SR141716A binding. Biochemistry. vol 44. issue 24. 2005-09-26. PMID:15952782. |
the human neuronal cannabinoid receptor (cb1) is a g-protein-coupled receptor (gpcr) triggered by the psychoactive ingredients in marijuana, as well as endogenous cannabinoids produced in the brain. |
2005-09-26 |
2023-08-12 |
human |
| J Ludovic Croxford, Takashi Yamamur. Cannabinoids and the immune system: potential for the treatment of inflammatory diseases? Journal of neuroimmunology. vol 166. issue 1-2. 2005-09-20. PMID:16023222. |
the presence of cannabinoid receptors on cells of the immune system and anecdotal and historical evidence suggesting that cannabis use has potent immuno-modulatory effects, has led to research directed at understanding the function and role of these receptors within the context of immunological cellular function. |
2005-09-20 |
2023-08-12 |
Not clear |
| C Trebst, M Stange. [Cannabinoids in multiple sclerosis -- therapeutically reasonable?]. Fortschritte der Neurologie-Psychiatrie. vol 73. issue 8. 2005-09-14. PMID:16052440. |
anecdotal reports from patients with multiple sclerosis (ms) experiencing relief of their spasticity and pain after smoking marihuana have prompted discussions about a potential therapeutic application of cannabis preparations in ms. only recently the first large, multicenter, double-blind, placebo controlled study was conducted evaluating the use of cannabinoids for treatment of spasticity and other symptoms related to ms. based on this trial and previous uncontrolled observations together with insights from basic research and animal experiments there is reasonable evidence for the therapeutical employment of cannabinoids in the treatment of ms related symptoms. |
2005-09-14 |
2023-08-12 |
Not clear |